Commentary
The prevalence of NAFLD is dramatically increasing in developed countries, but no approved therapy is available. Most of the current pharmacological strategies target comorbidities, such as manifestations of metabolic syndrome. In addition, none of used medications improve fibrosis, which is the strongest indicator of mortality in NAFLD.
In this review, A. Fougerat et al. (Institut National de la Recherche Agronomique, Toulouse, France) describe the determinants and mechanisms underlying the pathogenesis of NAFLD, its progression and complications, as well as the current therapeutic strategies that are employed.
They also focus on the complementary and distinct roles of PPAR isotypes in many biological processes and on the effects of PPAR agonists.
